BioSpace News Archive

Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) (“Portola " or the “Company”) for violations of federal securities laws.

Rakuten Medical, Inc. (RMI) a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020, in San Francisco.

Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today publishes topline results from its completed open-label Phase I/II clinical trial of Medigene’s autologous dendritic cell (DC) vaccine in 20 patients with acute myeloid leukemia (AML)

Tevosol, Inc., a clinical stage medical device company, and Texas Medical Center (TMC) Innovation, today announced that Tevosol has completed the TMCx accelerator program and established a base at TMC for FDA pivotal clinical trials and US commercial operations.

National leader advances its commitment to provide needed resources to strengthen Virginia communities

Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771 (expiration date June 2021) in 100 count bottles, NDC 51672-4131-1 to the consumer level

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the commencement of the EU field trial activities for the extended Immunohematology (IH) microarray.

BC Platforms, a world leader in genomic data management and analytics, today announced that it has formed a partnership with Dante Labs, a global genetic testing and data analysis company specialized in whole genome sequencing and interpretation intended both for Direct To Consumers and larger scale Life Science industry projects

TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announces unaudited preliminary revenue for the fourth quarter and full year 2019.

Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing.